Quick Answer
Enveric Biosciences, Inc. reported Operating Income of -$8.77 million for fiscal year 2025.
Enveric Biosciences, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$8.77M | +8.9% |
| 2024 | -$9.63M | +41.4% |
| 2023 | -$16.45M | +40.0% |
| 2022 | -$27.42M | +57.6% |
| 2021 | -$64.62M | -1050.4% |
| 2020 | -$5.62M | -144.6% |
| 2019 | -$2.30M | +67.9% |
| 2018 | -$7.15M | +34.4% |
| 2017 | -$10.90M | -102.5% |
| 2016 | -$5.38M | -16496.5% |
| 2014 | $32.8K | +20.6% |
| 2013 | $27.2K | +219.9% |
| 2012 | -$22.7K | +27.7% |
| 2011 | -$31.4K | +12.5% |
| 2010 | -$35.9K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.87M | +10.0% | +25.6% |
| June 30, 2025 | -$2.52M | -32.7% | -15.2% |
| March 31, 2025 | -$2.19M | +11.7% | -5.0% |
| September 30, 2024 | -$2.08M | +39.6% | -9.8% |
| June 30, 2024 | -$1.90M | +67.0% | +23.4% |
| March 31, 2024 | -$2.48M | +49.0% | +28.2% |
| September 30, 2023 | -$3.45M | +39.0% | +40.1% |
| June 30, 2023 | -$5.76M | -22.3% | -18.4% |
- Enveric Biosciences, Inc. showed an increase of +8.9% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, Enveric Biosciences, Inc.’s operating income has declined by 24358.4% (from -$35.9 thousand to -$8.77 million).
- The most recent figure is from Enveric Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: